Answers are grounded in this paper and cite their sources.
Purpose of Review Bipolar disorder (BD) is a complex and debilitating condition in which antidepressant-associated treatment-emergent mania (TEM) poses a significant clinical challenge. This narrative review synthesizes current insights into the neurobiological mechanisms underlying this phenomenon, aiming to update the understanding in the field. Recent Findings Clinical guidelines often caution against antidepressant monotherapy due to the risks of mood destabilization and switching, particularly in BD type I. A review of specific antidepressant classes reveals that tricyclic antidepressants (TCAs) carry a high risk of TEM, which has been linked to disruptions in cholinergic-adrenergic balance and heightened noradrenergic activity. Selective serotonin reuptake inhibitors (SSRIs), while less implicated than TCAs, are also associated with TEM, involving serotonin neurotransmission and potential interactions with muscarinic and histaminergic receptors. Furthermore, evidence suggests that even atypical antidepressants with non-monoaminergic profiles can induce manic switches, highlighting the vulnerability of some individuals and the influence of genetic predispositions. In addition, the effects of antidepressants associated with TEM can also be influenced by factors related to hepatic metabolism, as well as alterations in mitochondrial activity and immunoinflammatory processes, which can modulate the response to treatment and vulnerability to mood dysregulation. Summary Antidepressants are one possible precipitant of TEM, but the phenomenon is better understood as a vulnerability-dependent outcome rather than a universal consequence of antidepressant exposure. Current evidence suggests that TEM may arise from neurobiological perturbations that are partially distinct across antidepressant classes and interact with individual susceptibility factors. These findings point to a broader network-level dysregulation of mood that extends beyond isolated neurotransmitter systems. These observations reinforce the importance of personalized treatment strategies that prioritize mood stabilization, careful patient selection, and close clinical monitoring when antidepressants are used in bipolar depression.
No takes yet. Share an insight, caveat, or question.
Peper‐Nascimento et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: